stockportfolio.pro
Stocks / KMDA vs OVID
KMDA vs OVID
Kamada Ltd. and Ovid Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Kamada Ltd. (KMDA) | Ovid Therapeutics Inc. (OVID) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $180.46M | $7.25M |
| Net income (latest FY) | $20.20M | $-17.41M |
| Revenue growth (5y CAGR) | 11.7% | -10.5% |
| Net margin | 11.2% | -240.1% |
| Return on equity | 7.5% | -13.3% |
| P/E ratio | 20.9 | — |
| Dividend yield | 3.5% | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KMDA — free Open OVID — freeFrequently asked questions
Which is bigger, KMDA or OVID?
Kamada Ltd. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, KMDA or OVID?
Over the last five fiscal years, Kamada Ltd. grew revenue faster — 11.7%/yr versus -10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.